The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses

The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses

Abstract Mitiperstat is a myeloperoxidase inhibitor in clinical development for treatment of patients with heart failure and preserved or mildly reduced ejection fraction, non‐alcoholic steatohepatits and chronic obstructive pulmonary disease. We aimed to assess the risk of QT‐interval prolongation...

Full description

Bibliographic Details
Main Authors:	Joanna Parkinson, Jesper Sundell, Dinko Rekić, Karin Nelander, Hans Ericsson, Ahmad Ebrahimi, Corina Dota, Mikael Sunnåker
Format:	Article
Language:	English
Published:	Wiley 2024-04-01
Series:	Pharmacology Research & Perspectives
Subjects:	biopharmaceutics drug safety heart failure modeling and simulation QT prolongation
Online Access:	https://doi.org/10.1002/prp2.1184

Similar Items

Overdose of Quetiapine—A Case Report with QT Prolongation
by: Elisabetta Bertol, et al.
Published: (2021-12-01)

QT Changes of Unforeseen Implications and Bedaquiline: An Observational Study
by: Samya Dutta, et al.
Published: (2022-02-01)

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction
by: Karin Nelander, et al.
Published: (2021-05-01)

QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study)
by: Erande S, et al.
Published: (2019-06-01)

Association between C-reactive protein, corrected QT interval and presence of QT prolongation in hypertensive patients
by: Kai-Ting Chang, et al.
Published: (2014-06-01)

Methods of Assessment and Clinical Relevance of QT Dynamics
by: Beata Sredniawa, et al.
Published: (2005-07-01)

HCQ induced QT prolongation- Primum non nocere
by: A.J. Mahendran, et al.
Published: (2020-09-01)

Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study
by: Qasim Khan, et al.
Published: (2017-12-01)

Prolonged QT Syndrome Presenting as Epilepsy
by: J Gordon Millichap
Published: (1994-09-01)

Prognostic value of QT interval prolongation in patients with acute ischemic stroke
by: Iranmanesh F (MD), et al.
Published: (2012-12-01)

The association between insulin resistance and QT interval: A systematic review and Meta-Analysis
by: Maryam Mobasheri-Shiri, et al.
Published: (2025-02-01)

Long QT syndrome - causes and risk factors
by: Erwin Ciechański, et al.
Published: (2018-10-01)

Long QT syndrome - causes and risk factors
by: Erwin Ciechański, et al.
Published: (2018-10-01)

Associations of serum and dialysate electrolytes with QT interval and prolongation in incident hemodialysis: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study
by: Esther D. Kim, et al.
Published: (2019-04-01)

Drug-induced QT interval prolongation in cancer patients
by: Torben K. Becker, et al.
Published: (2011-12-01)

The best QT correction formula in a non-hospitalized population: the Fasa PERSIAN cohort study
by: Mohammad Hosein Yazdanpanah, et al.
Published: (2022-02-01)

QT Prolongation: Psychotropic medication versus illicit drugs
by: A. Florian, et al.
Published: (2022-06-01)

Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End‐Stage Kidney Disease
by: Magdalene M. Assimon, et al.
Published: (2020-07-01)

Ondansetron-induced QT prolongation among various age groups: a systematic review and meta-analysis
by: Kamaldeep Singh, et al.
Published: (2023-07-01)

Pheochromocytoma presenting with QT prolongation and catecholamine-induced myocarditis in a child
by: Kwannapas Saengsin, et al.
Published: (2023-01-01)

Long QT and death in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease is not related to electrolyte disorders
by: Zilberman-Itskovich S, et al.
Published: (2019-05-01)

Single intravenous dose ondansetron induces QT prolongation in adult emergency department patients: a prospective observational study
by: Mohammad Rezaei Zadeh Rukerd, et al.
Published: (2024-04-01)

The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review
by: Teuku Heriansyah, et al.
Published: (2020-11-01)

Prolongation of the QT Interval and Post-Extrasystolic Augmentation of the TU-Wave During Emotional Stress
by: Velislav N. Batchvarov, et al.
Published: (2008-04-01)

Hydroxychloroquine induced QT prolongation in a schizoaffective patient being treated for a COVID-19 infection: A Case Report
by: R. Amazan, et al.
Published: (2022-06-01)

Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
by: Ying Zhang, et al.
Published: (2023-12-01)

Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data
by: I Gusti Agung Ayu Putu Sri Darmayani, et al.
Published: (2022-07-01)

The effect of oral ondansetron on QT interval in children with acute gastroenteritis; a retrospective observational study
by: Heewon Yang, et al.
Published: (2021-11-01)

Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis
by: Oki Nugraha Putra, et al.
Published: (2022-01-01)

A case of hypoglycemiainduced QT prolongation leading to torsade de pointes and a review of pathophysiological mechanisms
by: Faris Hannoodi, et al.
Published: (2017-06-01)

Serial electrocardiogram recordings revealed a high prevalence of QT interval prolongation in patients with tuberculosis receiving fluoroquinolones
by: Ke-Shiuan Ju, et al.
Published: (2023-12-01)

Syncope with QT‐interval prolongation and T‐wave inversion in anterior and inferior leads: Foreboder of a life‐threatening condition?
by: Jing‐Xiu Li, et al.
Published: (2023-01-01)

Potential QT-prolonging drug-drug interactions in cardiovascular disease patients
by: Milena Kovačević, et al.
Published: (2025-01-01)

Effects of Antipsychotics on Arrhythmogenic Parameters in Schizophrenia Patients: Beyond Corrected QT Interval
by: Okayasu H, et al.
Published: (2021-01-01)

Antipsychotic Drugs and Sudden Death
by: Seyed Hesameddin Abbasi, et al.
Published: (2006-04-01)

Antipsychotic Drugs and Sudden Death
by: Khosro Afkham, et al.
Published: (2006-05-01)

Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer
by: Elizabeth J. Rowe, et al.
Published: (2022-12-01)

Family long QT syndrome type 2 associated with <em>KCNH2</em> gene mutation: aborted sudden cardiac death
by: Iván Alejandro Elizalde Uribe, et al.
Published: (2023-09-01)

Electrocardiographic Findings in Children Treated with Leuprolide Acetate for Precocious Puberty: Does it Cause Prolonged QT?
by: Esma Ebru Altun, et al.
Published: (2024-12-01)

QT Adaptation and Intrinsic QT Variability in Congenital Long QT Syndrome
by: Srikanth Seethala, et al.
Published: (2015-12-01)